WE CARE ABOUT RARE DISEASE PATIENTS

FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.

February is Rare Disease awareness month. Find out how you can "show your stripes" and other ways to get involved at rarediseaseday.us.